

Zydus launches eye disease blockbuster Aflibercept biosimilar alternative in India

Last year, Bengaluru-based Biocon Biologics also signed a settlement and licensing agreement with Regeneron, clearing the US market entry for its brand Yesafili (aflibercept-jbvf).



Ahmedabad: Zydus

Lifesciences has announced the launch of its blockbuster therapy aflibercept biosimilar version in India.

The commercial launch is announced following an agreement with the drug's patent owner Regeneron Pharmaceuticals, and Bayer, according to a company release which did not disclose the deal financial terms.

Zydus will market the drug under the brand name Anyra over multiple ophthalmic indication including Age-related Macular Degeneration (AMD), visual impairment due to macular edema secondary to Retinal Vein Occlusion (Branch RVO or Central RVO), visual impairment due to Diabetic Macular Edema (DME) and others.

Aflibercept is a vascular endothelial growth factor (VEGF) inhibitor, that helps stop the growth of abnormal blood vessels, by blocking VEGF— a signalling protein—reduce swelling, leakage, and further damage.

In 2025, Regeneron the US commercial rights holder aflibercept brand Eylea reported net sales of over \$4.3 billion, down 27 per cent from the previous year, as the drug encountered impact of emerging biosimilar competition.

“Anyra is a transformative step for affordable retinal care in India. By delivering a high-quality, indigenously developed Aflibercept 2 mg, we are expanding patient access to critical therapies with advanced biologics,” said Sharvil Patel, MD, Zydus Lifesciences.

Last year, Bengaluru-based Biocon Biologics also signed a settlement and licensing agreement with Regeneron, clearing the US market entry for its brand Yesafili (aflibercept-jbvf), an interchangeable biosimilar of Eylea (aflibercept).

Alongside them, Hyderabad-based Aurobindo Pharma’s biosimilars arm, CuraTeQ Biologics, is also developing an aflibercept biosimilar, which is currently in the Phase 3 clinical stage.

News Source:

<https://pharma.economictimes.indiatimes.com/news/drug-approvals-and-launches/zydus-launches-eye-disease-blockbuster-aflibercept-biosimilar-alternative-in-india/128553746>